A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Summary

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Timeline

Start

2022-06-10

Primary completion

2024-03-27

Completion

2024-03-27

Drugs

Indications